About Sangamo Therapeutics, Inc.
For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com.
|
|
|
201-500 employees
View all Sangamo Therapeutics, Inc. employees
|
|
Biotechnology
|
|
7000 Marina Blvd, Brisbane, California 94005, US
|
|
1995
|
|
Biotechnology, Gene Therapy, Cell Therapy, Immunology, Tauopathies, Genome Editing, Tauopathies, Genome Editing, Beta Thalassemia, Immunology, Fabry, Hemophilia A, Hemophilia B, Mps I, Mps Ii, Beta Thalassemia, Biotechnology, Fabry, Cell Therapy, Gene Therapy
|
Sangamo Therapeutics, Inc. Alternatives
Frequently Asked Questions about Sangamo Therapeutics, Inc.
Berna Demiray is the CEO of Sangamo Therapeutics, Inc.. To contact Berna Demiray email at [email protected].
The decision makers in Sangamo Therapeutics, Inc. are Amy Pooler, Antonio Vernacchio, Nathalie Duboisstringfellow, etc. Click to Find Sangamo Therapeutics, Inc. decision makers emails.
Sangamo Therapeutics, Inc. Staff Directory
Search Sangamo Therapeutics, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
